found in four melanoma patients with durable response to anti-PD-1 treatment (median PFS=2.3 years) higher pretreatment tumor CD8+T-cell infiltrates and significantly higher effector memory (CD8+/CCR7-/CD45RA-) but lower CD8+PD-1+and CD4+PD-1+cells compared to eight patients with a median PFS 1.6 months (77). This evidence concerns the gene CD8A and neoplasm.